Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|Obalon Therapeutics to Present at the Ca...||08/05/19|
|SAN DIEGO, Aug. 05, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-a...|
|Canaccord Genuity downgrades from Buy to Hold rating and lowers Price Target from $3.00 to $1.50|
|Roth Capital downgrades from Buy to Neutral rating and lowers Price Target from $6.00 to $2.75|
|Stifel Nicolaus upgrades from Hold to Buy rating and raises Price Target from $2.50 to $3.00|
|Date||2019-06-25 (BMO)||Est. (EPS/Rev.)||($0.31)/ 1.69M|
|Actual (EPS/Rev.)||/||EPS (TTM)||0|